Centro de Investigacion Biomedica en Red de Bioingenieria, Biomateriales y Nanomedicina (CIBER- BBN), Madrid, Spain.
Curr Drug Targets. 2018 Feb 8;19(3):213-224. doi: 10.2174/1389450117666160603023037.
BACKGROUND: Cancer is one of the major leading causes of death worldwide and its prevalence will be higher in the coming years due to the progressive aging of the population. The development of nanocarriers in oncology has provided a new hope in the fight against this terrible disease. OBJECTIVE: Among the different types of nanoparticles which have been reported in the scientific literature, mesoporous silica nanoparticles (MSNs) are very promising materials due to their inherent properties such as high loading capacity of many different drugs, excellent biocompatibility and easy functionalization. RESULTS: This review presents the current state of the art related to the development of mesoporous silica nanocarriers for antitumoral therapy paying special attention on targeted MSN able to selectively destroy tumoral cells, reducing the side damage in healthy ones, and the basic principles of targeting tumoral tissues and cells. CONCLUSIONS: MSNs constitute a promising nanomaterial for drug delivery applications in antitumoral therapy as a consequence of its unique properties such as excellent biocompatibility, high loading capacity, robustness, easy production and existence of multiple strategies for their functionalization with a myriad of bio-organic moieties. In the coming years, the clever application of this material would provide novel alternatives for the treatment of this complex disease.
背景:癌症是全球主要的死亡原因之一,由于人口的老龄化,未来其发病率将会更高。在肿瘤学中,纳米载体的发展为对抗这种可怕疾病提供了新的希望。
目的:在科学文献中报道的不同类型的纳米颗粒中,介孔硅纳米颗粒(MSNs)是一种非常有前途的材料,因为它们具有固有特性,如能够负载多种不同药物、具有极好的生物相容性和易于功能化等。
结果:本综述介绍了介孔硅纳米载体在抗肿瘤治疗方面的最新进展,特别关注能够选择性地破坏肿瘤细胞、减少对健康细胞的副作用的靶向 MSN,以及靶向肿瘤组织和细胞的基本原理。
结论:MSNs 作为一种很有前途的纳米材料,可用于抗肿瘤治疗的药物输送应用,这是由于其具有独特的性质,如极好的生物相容性、高负载能力、稳健性、易于生产以及存在多种方法可对其进行功能化,使其与多种生物有机基团结合。在未来几年,这种材料的巧妙应用将为这种复杂疾病的治疗提供新的选择。
Curr Drug Targets. 2018-2-8
Curr Top Med Chem. 2015
J Mater Sci Mater Med. 2018-5-8
Recent Pat Drug Deliv Formul. 2020
Adv Mater. 2012-2-29
Biomed Pharmacother. 2018-11-6
Int J Nanomedicine. 2024
Nanomaterials (Basel). 2019-4-2
Int J Mol Sci. 2019-2-20